SARC-F问卷筛查肌少症与老年女性身体表现:一项横断面研究
该横断面研究基于EPIDOS队列3025名社区老年女性(平均年龄80.5±3.9岁),评估SARC-F问卷筛查肌少症(以FNIH标准定义)的效度及其与身体表现的关系。SARC-F筛查肌少症患病率为16.7%,FNIH标准为1.8%;SARC-F敏感度34%、特异度85%。SARC-F定义的肌少症女性身体表现显著更差,且SARC-F提升了对不良身体表现的预测能力。
要点
- SARC-F问卷筛查肌少症敏感度仅34%,特异度85%,效度有限。
- SARC-F定义的肌少症女性身体表现显著低于非肌少症女性。
- SARC-F可提升临床特征对不良身体表现的预测价值。
核心结论
- SARC-F问卷与FNIH标准相比筛查肌少症的效度有限,但SARC-F定义的肌少症能显著提升临床特征对不良身体表现的预测价值。
研究设计与样本
- 横断面研究,数据来自Toulouse和Lyon的EPIDOS研究,纳入3025名无髋部骨折史的社区老年女性,平均年龄80.5±3.9岁。
主要发现
- SARC-F问卷(评分≥4定义肌少症)筛查的肌少症患病率为16.7%(n=504),FNIH标准定义的患病率为1.8%(n=49)。
- SARC-F诊断FNIH标准定义肌少症的敏感度为34%,特异度为85%。
- SARC-F定义的肌少症女性在膝关节伸展力量、6米步速和重复坐立测试等身体表现上显著低于非肌少症女性。
- SARC-F提升了模型预测不良身体表现的能力,调整R2用于确定模型解释各结局变异的百分比。
关键数值与推荐
- SARC-F自报问卷评分范围0-10分,评分≥4分定义肌少症。
- FNIH标准使用握力和经DXA评估的四肢瘦体重除以BMI来定义肌少症。
临床怎么用
- 在社区老年女性中,SARC-F问卷可作为初步筛查工具,但其低敏感度提示阴性结果不能排除肌少症。
- SARC-F阳性的老年女性应关注身体表现下降,可能需要进一步评估和干预。
局限性
- 横断面设计无法推断因果关系。
- 研究人群为社区老年女性,结果外推至男性或其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Screening for sarcopenia in daily practice can be challenging. Our objective was to explore whether the SARC-F questionnaire is a valid screening tool for sarcopenia (defined by the Foundation for the National Institutes of Health [FNIH] criteria). Moreover, we evaluated the physical performance of older women according to the SARC-F questionnaire. DESIGN: Cross-sectional study. PARTICIPANTS: Data from the Toulouse and Lyon EPIDémiologie de l'OStéoporose study (EPIDOS) on 3025 women living in the community (mean age: 80.5 ± 3.9 years), without a previous history of hip fracture, were assessed. MEASUREMENTS: The SARC-F self-report questionnaire score ranges from 0 to 10: a score ≥4 defines sarcopenia. The FNIH criteria uses handgrip strength (GS) and appendicular lean mass (ALM; assessed by DXA) divided by body mass index (BMI) to define sarcopenia. Outcome measures were the following performance-based tests: knee-extension strength, 6-m gait speed, and a repeated chair-stand test. The associations of sarcopenia with performance-based tests was examined using bootstrap multiple linear-regression models; adjusted R2 determined the percentage variation for each outcome explained by the model. RESULTS: Prevalence of sarcopenia was 16.7% (n = 504) according to the SARC-F questionnaire and 1.8% (n = 49) using the FNIH criteria. Sensibility and specificity of the SARC-F to diagnose sarcopenia (defined by FNIH criteria) were 34% and 85%, respectively. Sarcopenic women defined by SARC-F had significantly lower physical performance than nonsarcopenic women. The SARC-F improved the ability to predict poor physical performance. CONCLUSION: The validity of the SARC-F questionnaire to screen for sarcopenia, when compared with the FNIH criteria, was limited. However, sarcopenia defined by the SARC-F questionnaire substantially improved the predictive value of clinical characteristics of patients to predict poor physical performance.
引用
- Rolland Y, Dupuy C, Abellan Van Kan G, et al. Sarcopenia Screened by the SARC-F Questionnaire and Physical Performances of Elderly Women: A Cross-Sectional Study. J Am Med Dir Assoc. 2017. PMID: 28629717. doi:10.1016/j.jamda.2017.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。